Core Viewpoint - Fosun International (00656.HK) announced plans for share buybacks by its controlling shareholder and senior management, reflecting confidence in the company's growth potential and long-term investment value, despite a recent profit warning indicating expected losses for 2025 [2] Group 1: Share Buyback Plans - The controlling shareholder, Fosun Holdings Limited, and senior management plan to increase their holdings in the company within 12 months following the announcement of the 2025 annual results [2] - The total amount for the proposed share buyback will not exceed HKD 500 million, in compliance with the Hong Kong Stock Exchange's rules regarding minimum public float [2] Group 2: Financial Outlook - Fosun International issued a profit warning, projecting a loss between RMB 21.5 billion and RMB 23.5 billion for the year 2025 [2]

Core Viewpoint - Fosun International (00656.HK) announced a plan to repurchase up to HKD 500 million of its shares within 12 months after the release of its 2025 annual results, following a previous announcement to buy back up to HKD 1 billion in shares, aimed at boosting market confidence [1][3][8] Group 1: Share Buyback and Management Communication - The share buyback plan is based on the company's judgment of its long-term development prospects [3][8] - On March 8, prior to the buyback announcement, the company held an investor conference call where management reiterated its commitment to a strategic direction focused on "streamlining and concentrating on core businesses" [3][8] - Management indicated that a one-time non-cash impairment charge would help solidify the financial statements and create conditions for future profit release, maintaining confidence in achieving a profit target of HKD 10 billion over the next three to five years [3][8] Group 2: Financial Performance and Impairment Charges - On March 6, the company issued a profit warning, projecting a net loss attributable to shareholders of approximately RMB 21.5 billion to RMB 23.5 billion for the 2025 fiscal year, primarily due to one-time non-cash impairment charges related to certain real estate projects and goodwill from non-core businesses [4][9] - The company stated that the ongoing downturn in the real estate sector has led to impairment signs in some projects, prompting significant asset impairment provisions [5][9] - Management emphasized that these impairment charges are accounting adjustments and do not affect the overall operations and cash flow of the company [5][10] Group 3: Core Business Growth and Future Outlook - Despite the anticipated accounting losses, several core subsidiaries of Fosun have reported growth in their 2025 operating data [6][11] - In the pharmaceutical sector, Fosun Pharma (600196.SH, 02196.HK) reported revenue of RMB 29.393 billion and a net profit of RMB 2.523 billion for the first three quarters of 2025 [6][11] - The insurance segment showed positive results, with Fosun Portugal Insurance achieving a Standard & Poor's A rating and a net profit of EUR 1.7 million, up 11.7% year-on-year [6][11] - Domestic insurance operations, including Fosun United Health Insurance and Fosun Baodexin Life Insurance, reported significant revenue and profit growth, with the latter's net profit increasing over 450% [6][11] - Management remains confident in achieving the HKD 10 billion profit target within three to five years and aims to reduce total liabilities to below RMB 60 billion, indicating a new development cycle starting in 2026 [6][11]

Core Viewpoint - Fosun International plans to enhance shareholder confidence through share buybacks and management's commitment to increase holdings, signaling a focus on long-term growth despite recent financial losses [1][2][4] Group 1: Shareholder Actions - Fosun International's controlling shareholder and executives will increase their holdings by up to HKD 500 million within 12 months after the 2025 annual results announcement [1] - The company plans to repurchase shares in the open market for a total amount not exceeding HKD 1 billion from the 2025 results announcement until the 2026 annual general meeting [1] Group 2: Financial Performance and Strategy - Fosun International anticipates a significant loss of approximately RMB 215 billion to RMB 235 billion for the fiscal year 2025, primarily due to one-time non-cash impairment charges [2] - The company is strategically focusing on its core businesses by exiting non-core assets and has implemented a "slimming down" strategy to improve asset quality and operational performance [2][4] Group 3: Core Business Growth - The core sectors of Fosun, including healthcare and insurance, are showing improved asset and profit quality, with significant revenue growth reported in the pharmaceutical sector [4][5] - Fosun Pharma reported a revenue of RMB 29.393 billion and a net profit of RMB 2.523 billion for the first three quarters of 2025, marking a year-on-year increase of 25.5% [4] - The insurance segment also demonstrated strong performance, with Fosun's Portuguese insurance achieving a net profit of EUR 1.7 million, up 11.7% year-on-year [5][6] Group 4: Future Outlook - Management expressed confidence in achieving a profit target of RMB 10 billion over the next three to five years while optimizing financial structure and reducing total liabilities below RMB 60 billion [6] - The company is entering a new development cycle in 2026, with a positive outlook for future growth [6]

智通财经APP讯， 发布公告，公司于2026年3月6日收到公司控股股东复星控股有限公司(控股股东)及高 级管理人员(高管)的通知，基于对集团的前景及增长潜力充满信心，以及对公司长远投资价值的认可， 控股股东及高管计划自公司2025年度业绩公告发布后的12个月内于公开市场交易中增持公司股份。 复星国际(00656)发布公告，公司于2026年3月6日收到公司控股股东复星控股有限公司(控股股东)及高级 管理人员(高管)的通知，基于对集团的前景及增长潜力充满信心，以及对公司长远投资价值的认可，控 股股东及高管计划自公司2025年度业绩公告发布后的12个月内于公开市场交易中增持公司股份。 控股股东及高管对公司股份的任何买入均将严格遵守香港联合交易所有限公司证券上市规则、所有适用 法律及公司的内部控制及证券交易政策。根据上市规则有关最低公众持股量的规定，为确保公司持续符 合相关要求，控股股东及高管本次拟增持公司股份的总金额不超过港币5亿元。 ...

免责声明：本文内容与数据由观点根据公开信息整理，不构成投资建议，使用前请核实。 观点网讯：3月9日，复星国际有限公司发布公告称，基于对集团前景及增长潜力的信心，以及对公司长 远投资价值的认可，其控股股东复星控股有限公司及公司高级管理人员计划自2025年度业绩公告发布后 的12个月内，通过公开市场增持公司股份。 根据公告内容，本次增持行为将严格遵守香港联合交易所有限公司证券上市规则、适用法律及公司内部 证券交易政策。为满足最低公众持股量要求，增持总金额不超过港币5亿元。 公告同时提示，股东及潜在投资者应注意，本次增持计划可能因资本市场变化或其他不可预判因素而无 法或部分无法实施，买卖公司证券时应审慎行事。 ...

Core Viewpoint - Fosun International plans to enhance shareholder confidence through share buybacks and management's commitment to increase holdings, signaling a focus on long-term growth despite recent financial losses due to asset impairment [1][2][4] Group 1: Shareholder Actions - On March 6, Fosun International announced that its controlling shareholders and executives would increase their holdings by up to HKD 500 million within 12 months after the 2025 annual results announcement [1] - The company also plans to repurchase shares in the open market for a total amount not exceeding HKD 1 billion from the 2025 results announcement until the 2026 annual general meeting [1] Group 2: Financial Performance and Strategy - Fosun International issued a profit warning on March 6, projecting a loss of approximately RMB 21.5 billion to RMB 23.5 billion for the fiscal year 2025, primarily due to one-time non-cash impairment charges [2] - The company is focusing on its core businesses and has initiated a strategy of "streamlining and focusing on main operations," which includes significant asset impairment to improve transparency and asset quality [2][4] Group 3: Core Business Growth - The core sectors of Fosun, including healthcare and insurance, are showing positive growth, with Fosun Pharma reporting revenue of RMB 29.393 billion and a net profit of RMB 2.523 billion for the first three quarters of 2025, a year-on-year increase of 25.5% [4] - In the insurance sector, Fosun's Portuguese insurance received an A rating from S&P, with a net profit of EUR 1.7 million for the first three quarters of 2025, reflecting an 11.7% increase [5][6] Group 4: Future Outlook - Management expressed confidence in achieving a profit target of RMB 10 billion over the next three to five years while optimizing financial structure and reducing total liabilities to below RMB 60 billion [6] - The company anticipates entering a new development cycle in 2026, with a strong focus on growth and profitability [6]

根据香港交易所公告，复星国际表示，控股股东复星控股和高级管理人员计划自公司2025年度业绩公告 发布后的12个月内于公开市场交易中增持公司股份；总金额不超过5亿港元（6400万美元）。 来源：滚动播报 ...

3月9日早间，复星国际在港交所公告，公司于2026年3月6日收到公司控股股东复星控股有限公司及高级 管理人员的通知，控股股东及高管计划自公司2025年度业绩公告发布后的12个月内于公开市场交易中增 持公司股份。根据上市规则有关最低公众持股量的规定，为确保公司持续符合相关要求，控股股东及高 管本次拟增持本公司股份的总金额不超过港币5亿元。 ...

控股股东及高管对公司股份的任何买入均将严格遵守香港联合交易所有限公司证券上市规则、所有适用 法律及公司的内部控制及证券交易政策。根据上市规则有关最低公众持股量的规定，为确保公司持续符 合相关要求，控股股东及高管本次拟增持公司股份的总金额不超过港币5亿元。 智通财经APP讯，复星国际(00656)发布公告，公司于2026年3月6日收到公司控股股东复星控股有限公司 (控股股东)及高级管理人员(高管)的通知，基于对集团的前景及增长潜力充满信心，以及对公司长远投 资价值的认可，控股股东及高管计划自公司2025年度业绩公告发布后的12个月内于公开市场交易中增持 公司股份。 ...

Core Viewpoint - Fosun International (00656) announced that its controlling shareholder, Fosun Holdings Limited, and senior management plan to increase their shareholding in the company within 12 months after the announcement of the company's 2025 annual results, reflecting confidence in the group's prospects and long-term investment value [1] Group 1 - The controlling shareholder and senior management will strictly comply with the Hong Kong Stock Exchange's listing rules, applicable laws, and the company's internal control and securities trading policies during the share buyback [1] - The total amount for the proposed share buyback will not exceed HKD 500 million to ensure compliance with the minimum public float requirements set by the listing rules [1]